Bruker Corporation
NASDAQ:BRKRMedical - Devices
-$1.07 today
- Market cap
- $9.66B
- Beta
- 1.30
- P/E (TTM)
- -718.1
- EPS (TTM)
- -$0.08
- Dividend yield
- 0.37%
Volume 1.73M
Average 2.41M
BRKR Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Bruker CorporationNASDAQ: BRKR
Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Investing cash flow declines year over year
Q2 FY2026 investing cash flow of $25.3M (cash outflow) fell 72.2% year over year, behind the -41.2% change in trailing-twelve-month investing cash flow. Sequentially, it fell 36.3% from the prior quarter. Over 3 fiscal years it compounded at -7.9% a year.
Context
- Investing cash flow amounted to 5.7% of revenue in FY2025, down 46.5 pp from a year earlier.
- Investing cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -72.2% toward the trailing-twelve-month pace of -41.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (196.5M) USD
- Year-over-year change
- +88.8%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (196.5M) | +88.8% |
| FY2024 | 2024-12-31 | (1.76B) | -439.0% |
| FY2023 | 2023-12-31 | (326M) | -29.6% |
| FY2022 | 2022-12-31 | (251.6M) | -30.8% |
| FY2021 | 2021-12-31 | (192.4M) | — |
Investing Cash Flow vs competitors
How BRKR compares with its peers on the latest reported figures
- BRKR's LTM Jun 2026 investing cash flow of $144.3M is the 7th largest of the 11 companies compared; the peer median is $204.85M.
- Its year-over-year change of -41.2% is the 9th highest of 11, against a peer median of +36.0%.
- Investing cash flow amounts to 4.1% of revenue for BRKR, versus a peer median of 10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $11.08B | +635.7% | -18.8% | 43.3% | |
| LTM Sep 2026 | $7.98B | +62.3% | +23.3% | 16.9% | |
| LTM Jul 2026 | $1.29B | +2.7% | +5.2% | 17.5% | |
| LTM Jun 2026 | $242.15M | +51.6% | -25.1% | 11.5% | |
| LTM Jun 2026 | $237.1M | +19.3% | -46.0% | 9.2% | |
| LTM Jun 2026 | $172.61M | +20.5% | +11.6% | 4.2% | |
| LTM Jun 2026 | $144.3M | -41.2% | -7.9% | 4.1% | |
| LTM Mar 2026 | $106.07M | -47.8% | -0.2% | 66.3% | |
| LTM Jul 2026 | $83.26M | -112.7% | -49.3% | 2.9% | |
| LTM Jul 2026 | $29.35M | +118.0% | +12.1% | 0.6% | |
| LTM Sep 2026 | $22.72M | +76.2% | -59.1% | 1.9% | |
| Peer median (excluding BRKR) | $204.85M | +36.0% | -9.5% | 10.3% | |
Competitors are the stored peer set for BRKR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 280.6M | 298.5M | 427.2M | 113.8M | (8.3M) |
| Depreciation & Amortization | 89.1M | 88.7M | 114.9M | 183.8M | 220.3M |
| Deferred Income Tax | (5.8M) | (14.8M) | (24.4M) | (63.8M) | (104.5M) |
| Stock-Based Compensation | 17.2M | 27.7M | 24M | 25.3M | 20.2M |
| Change in Working Capital | (125.2M) | (144.1M) | (87.8M) | (78.2M) | (144.8M) |
| Accounts Receivables | (95.3M) | (67.9M) | (900K) | (40.6M) | 54.2M |
| Inventory | (67M) | (137.9M) | (125M) | (69.8M) | 12.1M |
| Accounts Payables | 61.8M | 33.3M | 23.1M | 20.8M | (37.5M) |
| Other Working Capital | (24.7M) | 28.4M | 15M | 11.4M | (173.6M) |
| Other Non-Cash Items | 26.5M | 18.4M | (103.8M) | 70.4M | 151.2M |
| Operating Cash Flow | 282.4M | 274.4M | 350.1M | 251.3M | 134.1M |
| Capital Expenditures | (92M) | (129.2M) | (106.9M) | (115.3M) | (120.2M) |
| Acquisitions (Net) | (65M) | (182.3M) | (226.6M) | (1.6B) | (73.9M) |
| Purchases of Investments | (148.5M) | (60.2M) | (24.8M) | (48.3M) | (7.2M) |
| Sales of Investments | 108.2M | 106.2M | 21.2M | 4.8M | 0 |
| Other Investing Activities | 4.9M | 13.9M | 11.1M | 1.1M | (24.6M) |
| Investing Cash Flow | (192.4M) | (251.6M) | (326M) | (1.76B) | (196.5M) |
| Debt Repayment | 489.7M | (110.7M) | (21.5M) | 875.9M | (491.3M) |
| Common Stock Issued | 7M | 2.8M | 9.5M | 403M | 669.7M |
| Common Stock Repurchased | (153.3M) | (263.1M) | (152.3M) | 0 | (10M) |
| Dividends Paid | (24.2M) | (29.8M) | (29.4M) | (30.2M) | (22.8M) |
| Other Financing Activities | (500K) | (14.5M) | 300K | (18.9M) | (10.5M) |
| Financing Cash Flow | 318.7M | (415.3M) | (193.4M) | 1.23B | 135.1M |
| Effect of Forex Changes | (22.5M) | (30.5M) | 12.2M | (28.7M) | 43.7M |
| Net Change in Cash | 386.2M | (423M) | (157.1M) | (304.9M) | 116.4M |
| Free Cash Flow | 190.4M | 145.2M | 243.2M | 136M | 13.9M |
Bruker Corporation
NASDAQ:BRKR
Intrinsic Alpha fair value
Locked
Current Price
$63.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.